{"entity":{"id":"nct06613009","kind":"trial","name":"Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 1 trial of IBI3009 in unresectable, metastatic or extensive-stage small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer is a phase 1 interventional study registered as NCT06613009 by Innovent Biologics (Suzhou) Co. Ltd.; 190 participants are planned, it started on 2024-12-30; the registry gives 2027-08-30 as its primary completion date. Interventions recorded: IBI3009. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06613009","url":"https://clinicaltrials.gov/study/NCT06613009"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi3009"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06613009","phase":"1","setting":"A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","started":"2024-12-30","enrolled":190,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06613009/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"ibi3009","kind":"drug","name":"IBI3009","route":"/drugs/ibi3009/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}